Hideki Enokida

Evaluation of clinical prognostic factors for radium-223 therapy in castration-resistant prostate cancer with bone metastases: the KYUCOG-1901 study

We evaluated clinical factors associated with symptomatic skeletal events (SSEs), radiographic progression-free survival (rPFS), and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) and bone metastases treated with radium-223 (Ra-223)...